Body weight gain rather than body weight variability associated with increased risk of nonalcoholic fatty liver disease

Abstract Weight loss, the most established therapy for nonalcoholic fatty liver disease (NAFLD), is frequently followed by weight regain and fluctuation. The aim of this study was to investigate whether body weight change and variability were independent risk factors for incident NAFLD. We conducted...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Eun Ju Cho, Su Jong Yu, Gu Cheol Jung, Min-Sun Kwak, Jong In Yang, Jeong Yoon Yim, Goh Eun Chung
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/9e494caba5ea45a19d4186a2ea95dae4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract Weight loss, the most established therapy for nonalcoholic fatty liver disease (NAFLD), is frequently followed by weight regain and fluctuation. The aim of this study was to investigate whether body weight change and variability were independent risk factors for incident NAFLD. We conducted a longitudinal cohort study. Among the 1907 participants, incident NAFLD occurred in 420 (22.0%) cases during median follow-up of 5.6 years. In the multivariate analysis, there was no significant association between weight variability and the risk of incident NAFLD. The risk of incident NAFLD was significantly higher in subjects with weight gain ≥ 10% and 7% < gain ≤ 10% [hazard ratios (HR), 2.43; 95% confidence intervals (CI), 1.65–3.58 and HR, 1.73; 95% CI, 1.26–2.39, respectively], while the risk of incident NAFLD was significantly lower in those with −7% < weight loss ≤ -−3% (HR, 0.33; 95% CI, 0.22–0.51). Overall body weight gain rather than bodyweight variability was independently associated with the risk of incident NAFLD. Understanding the association between body weight variability and incident NAFLD may have future clinical implications for the quantification of weight loss as a treatment for patients with NAFLD.